Speaker

Gregory Daniel, PhD, MPH is Vice President, Head of Policy Innovation, Evidence & Engagement at Eli Lilly and Company. Greg has led the Global Public Policy group, responsible for evaluating and developing public policy concepts in areas such as prescription drug access, affordability and innovation, global value-based healthcare, health equity, and other high priority policy areas.  Greg also leads policy evidence development and external engagement, developing partnerships with academic groups, think-tanks, and other policy research organizations to advance policies that support innovation, access and affordability. He is also currently the Editor-in-Chief of Therapeutic Innovation and Regulatory Science (TIRS), the scientific journal of DIA.  Greg also serves on the Board of Directors and is Past President for the Innovation in Value Initiative (IVI) Foundation, is Adjunct Associate Professor at the Eshelman School of Pharmacy at the University of North Carolina-Chapel Hill and is Visiting Scholar at the Center of Innovation in Regulatory Science at the Duke-National University of Singapore.

Prior to joining Eli Lilly, Greg held the positions of Head of US Healthcare Policy at Edwards Lifesciences; Deputy Center Director and Clinical Professor at the Duke-Margolis Center for Health Policy; Fellow and Managing Director in the Center for Health Policy at the Brookings Institution; and Vice President, Government and Academic Research at Carelon (formerly HealthCore, subsidiary of Elevance).

Greg received his PhD in pharmaceutical economics, policy and outcomes from the University of Arizona, and an MPH focused in biostatistics, MS, and BS in Pharmacy all from The Ohio State University.